Product Description
Aldosterone is a mineralocorticoid hormone produced in the zona glomerulosa of the adrenal cortex that influences water and salt regulation in the body. Aldosterone's primary function is to act on the late distal tubule and collecting duct of nephrons in the kidney, favoring sodium and water reabsorption and potassium excretion while also contributing to acid-base balance. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK470339/)
Mechanisms of Action: MCRA Agonist, Mineralocorticoid Receptor Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous, Oral, Percutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: China | France | Ireland | Italy
Approved Indications: None
Company: Alere San Diego
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Hypertension|Ischemic Stroke|Ischemic Attack, Transient|Kidney Diseases|Membranous Nephropathy|Heart Failure, Chronic|Heart Block|Myocardial Infarction|Neuromyelitis Optica|Coronary Stenosis|Stroke|Type 2 Diabetes|Heart Failure, Systolic|Coronary Disease|Glomerulonephritis, Membranous|Hypertension, Renal|Kidney Failure, Chronic|Heart Failure|Cardiomyopathy, Dilated|Anesthesia Related
Phase 3: Myocardial Infarction|Hypertension|Heart Failure|Membranous Nephropathy|Atrial Fibrillation|Stroke|Glomerulonephritis, Membranous|Kidney Diseases
Phase 2: Heart Failure, Acute|Coronary Disease
Phase 1: Heart Failure|Inflammation
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07560982 |
ad-HUB | N/A |
Recruiting |
Heart Failure |
2031-07-01 |
2026-07-07 |
Primary Endpoints|Start Date|Treatments|Trial Status |
|
ChiCTR2500105869 |
ChiCTR2500105869 | N/A |
Recruiting |
Adenoma|Hyperaldosteronism |
2027-06-30 |
|||
ChiCTR2600123153 |
PREPARE | N/A |
Not yet recruiting |
Adenoma |
2027-06-30 |
|||
NCT07444203 |
TRIDENT 2 | N/A |
Recruiting |
Kidney Failure, Chronic|Type 2 Diabetes|Diabetic Nephropathy |
2027-05-30 |
2026-03-03 |
Primary Endpoints|Treatments |
|
ACTRN12626000198325 |
PIVOT-HDP | N/A |
Not yet recruiting |
Pre-Eclampsia|Pregnancy Complications, Cardiovascular|Kidney Diseases|Coronary Disease|Pregnancy Outcomes|Hypertension, Renal |
2026-12-31 |
2026-02-19 |
Treatments |
|
NCT05405101 |
WAVE | N/A |
Active, not recruiting |
Hyperaldosteronism |
2026-11-01 |
2026-07-20 |
||
ChiCTR2300074711 |
ChiCTR2300074711 | N/A |
Recruiting |
Heart Failure, Chronic |
2026-09-01 |
2023-08-16 |
Treatments |
|
ChiCTR2200059892 |
ChiCTR2200059892 | N/A |
Recruiting |
Kidney Diseases |
2026-04-30 |
2023-03-19 |
Treatments |
|
ChiCTR2300075447 |
ChiCTR2300075447 | N/A |
Not yet recruiting |
Heart Failure |
2025-12-30 |
2023-09-06 |
Treatments |
|
ChiCTR2500101073 |
ChiCTR2500101073 | N/A |
Recruiting |
Hypertension |
2025-11-30 |
|||
ChiCTR2500101167 |
ChiCTR2500101167 | N/A |
Not yet recruiting |
Resistant Hypertension |
2025-09-30 |
|||
ChiCTR2600119124 |
ChiCTR2600119124 | N/A |
/Completed |
Hypertension |
2025-03-31 |
|||
NCT05636995 |
H.A.P.P.I. Trial | N/A |
Active, not recruiting |
Hypertension|Hyperaldosteronism|Pregnancy Outcomes |
2025-03-01 |
2025-01-16 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
ChiCTR2400085282 |
ChiCTR2400085282 | N/A |
Recruiting |
Heart Failure |
2024-11-30 |
2024-06-05 |
Treatments |
|
ACTRN12623001340628 |
CONSEP | N/A |
Recruiting |
Hypertension |
2024-08-30 |
2026-02-15 |
Treatments |
|
NCT06236698 |
The value of 24h UA | N/A |
Completed |
Hyperaldosteronism|Hypertension |
2024-03-30 |
2025-04-17 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
ACTRN12618002044202 |
AFTER-AKI | N/A |
Recruiting |
Kidney Diseases|Acute Kidney Injury |
2023-06-30 |
2026-02-22 |
Treatments |
|
NCT05446779 |
SuddenDeath | N/A |
Active, not recruiting |
Hyperaldosteronism|Cushing Syndrome|Pheochromocytoma |
2023-01-31 |
2024-04-17 |
||
NCT05087940 |
TRYCORT | N/A |
Completed |
Resistant Hypertension |
2022-12-31 |
2023-02-24 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Treatments|Trial Status |
|
NCT04556279 |
AldoSalt | N/A |
Withdrawn |
Hyperaldosteronism|Hypertension |
2022-02-01 |
2024-05-11 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
|
NCT03029806 |
2015P002540 | N/A |
Active, not recruiting |
Hypertension, Renal |
2022-01-02 |
2023-02-10 |
Primary Endpoints |
|
NCT04078425 |
Sharidi | P1 |
Unknown status |
Heart Failure |
2022-03-01 |
2022-05-03 |
Primary Endpoints |
|
NCT07281014 |
NCT07281014 | P4 |
Recruiting |
Heart Failure |
2027-08-01 |
2026-02-20 |
Primary Endpoints|Start Date |
|
NCT05839314 |
HE-202009 | P4 |
Recruiting |
Membranous Nephropathy|Glomerulonephritis, Membranous|Kidney Diseases |
2027-05-03 |
2024-06-05 |
||
NCT04286399 |
ADOPT | P4 |
Recruiting |
Neuromyelitis Optica|Heart Failure, Systolic|Myocardial Infarction|Hypertension|Type 2 Diabetes|Coronary Disease|Heart Block|Stroke|Heart Failure, Chronic|Coronary Stenosis |
2022-06-30 |
2021-05-01 |
Primary Completion Date|Primary Endpoints|Start Date|Treatments |